Need to model drug contracts faster and more accurately? Our CXO and Founder, Nico Julian Mros, explains how the Lyfegen Drug Contracting Simulator’s advanced features can streamline and optimize your contracting processes. Explore different pricing options and contract scenarios with our solution, providing valuable support in your decision-making process. #drugpricing #healthcareinnovation #marketaccess
Lyfegen
Krankenhäuser und Gesundheitseinrichtungen
Basel, Basel-Town 20.901 Follower:innen
Accelerating value-based healthcare for patients
Info
We are a digital ecosystem for the healthcare industry, built upon trust, to enable value-based healthcare. Today, the way the majority of healthcare is delivered and paid for is unsustainable, for patients and industry stakeholders alike. The shift to value-based pricing & contracting is inevitable. That’s why we work to raise the standards and increase value in the healthcare industry. We from Lyfegen found a solution to break down existing barriers to sustainable healthcare. Our platform allows trusted, automated and scalable healthcare pricing. The platform integrates to various data sources to retrieve patient outcomes for given cohorts and determine the price payable based on the conditions sets by the manufacturer and payers. Using smart contracts and distributed ledger technology, we enable patients, payers, providers and manufacturers to enter value-based pricing agreements with immutable outcome data, near real-time reimbursement notifications, minimal administrative burden and highest data security. We envision a future where innovative treatments and quality healthcare are available to everyone. Where everything from healthcare systems, to data and delivery is sustainable and progressive.
- Website
-
https://lyfegen.com
Externer Link zu Lyfegen
- Branche
- Krankenhäuser und Gesundheitseinrichtungen
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Basel, Basel-Town
- Art
- Privatunternehmen
- Gegründet
- 2018
- Spezialgebiete
- Value-based healthcare, value-based pricing, value-based contracting, value based, healthcare, value, outcome based, Pharma, Market Access, Pricing, Real World Evidence, Health Outcomes, Patient Reported Outcomes, PROMS, value-based payments, EHR, FHIR, Interoperability, Patient Support Program, Early Access Schemes, Clinical Data, health economics, cost avoidance, ICHOM, value-based outcome measurement, QALY, patient-centric, digital health, Access, Rebate Management, Revenue Management und Managed Entry Agreements
Produkte
Orte
-
Primär
Wegbeschreibung
Aeschenvorstadt
Basel, Basel-Town 4051, CH
-
Wegbeschreibung
400 W 42nd St
New York, NY 10036, US
Beschäftigte von Lyfegen
-
Antti Hietala
Product Owner at Lyfegen.
-
Ronen Fischler
Transformational Leader in SaaS, AI & Data Analytics | Pivoting and Scaling Businesses | Championing Digital Disruption, Innovation, and Product…
-
Guido Mitchell
Commercial Leader & General Manager in MedTech | Driving business in mature & emerging markets | Digital Healthcare
-
Filiberto Becerra
Marketing Strategist | Growth Specialist | B2B - B2C Marketing | Demand Generation | Digital Innovation | Branding | Product Marketing
Updates
-
We are honored to receive the Swiss Economic Forum SEF.Growth High Potential Label. This recognition reflects the hard work and dedication of our entire team. At Lyfegen, we are committed to improving patient care by streamlining the processes for health insurers. The impact of our work ensures that vital treatments are more accessible to those who need them most. Read more about our journey in the SEF article: https://lnkd.in/deRYFAEX #SEF #Lyfegen #ScaleUp #SuccessStory #Innovation
Imagine you have a rare disease and there is a new drug to treat it, but health insurers won't cover it until the price is set. 💊 The speed of these negotiations is crucial. That's where Lyfegen, co-founded by Michel Mohler, Nico Julian Mros and Girisha Fernando, comes in. Lyfegen has developed a revolutionary rebate management calculator that speeds up and simplifies this process for health insurers. Without this platform, health insurers miss out on up to 30% of rebates due to complexity and lack of overview. This needs to change – effortlessly and to the benefit of all parties involved. Read more about Lyfegen's success story in our article: https://lnkd.in/eE9BepN3 Congratulations to the whole team of Lyfegen for the well-deserved SEF.Growth High Potential Label! 👏🏼 #SEF #Growth #highpotential #scaleup #SuccessStory #innovation
-
-
We are excited to introduce Denisa-Mariana Filip, a talented Full Stack Developer now part of Lyfegen’s tech team! Denisa brings a wealth of experience and a passion for technology, from her early days in informatics to her innovative work in cybersecurity and web development. We sat down with Denisa for an interview — discover how she’s contributing to our mission at Lyfegen: https://lnkd.in/dbZc3qah #HealthcareTechnology #MeetTheTeam
-
Can Medicare handle the projected $3.5 billion cost for new Alzheimer's treatments by 2025? Beta amyloid-directed monoclonal antibodies like Kisunla (donanemab) offer hope, but managing costs is crucial. Learn how Medicare plans to navigate these challenges and what it means for future treatments in our new article: #Alzheimers #Healthcare #Medicare #MedicalCosts #InnovativeTreatments #HealthcareManagement
Alzheimer’s disease treatments offer hope, but managing costs is a concern
Lyfegen auf LinkedIn
-
Vertex Pharmaceuticals is taking legal action against the U.S. government to ensure fertility support services for patients treated with Casgevy, their CRISPR-based gene therapy for sickle cell disease (SCD). Casgevy, which has shown promising results in reducing painful vaso-occlusive crises (VOCs), carries a risk of infertility due to the high-dose chemotherapy required for treatment. Vertex argues that current federal rules hinder their ability to provide necessary fertility preservation services, a crucial consideration for many patients. For more insights into public agreements on sickle cell disease, visit Lyfegen's agreements library. Book a demo today to learn more: lyfegen.com/demo #SickleCellDisease #GeneTherapy #HealthcareInnovation #Vertex #HealthEquity
-
Lyfegen hat dies direkt geteilt
We are excited to share that Lyfegen has been recognized in the F6S list of Top Healthcare Companies and Startups in Switzerland! F6S is a global online community connecting over 4 million founders and startups with resources such as funding, accelerators, grants, and networking opportunities. Being featured on this list is a tremendous honor for us. It is inspiring to see so many innovative and dedicated healthcare startups striving alongside us to make a difference in the industry. Are you curious to know more about our value-based solutions? Book a free demo with us today: lyfegen.com/demo #F6S #healthcareinnovation #Milestone #healthtechswitzerland
-
-
Cystic fibrosis (CF) creates serious obstacles for patients, impacting their lungs and digestive systems. In a major breakthrough, NHS England has finalized a long-term deal with Vertex Pharmaceuticals, guaranteeing ongoing access to critical CF medicines like Kaftrio, Symkevi, and Orkambi for both children and adults. This agreement resolves a lengthy cost dispute with NICE, highlighting the transformative benefits of these treatments for patients. Explore over 5,000 agreements in Lyfegen’s comprehensive Agreements Library, the largest global resource of its kind: https://lnkd.in/euuJz8sC #HealthcareInnovation #CysticFibrosis #Pharmaceuticals #NHS #PatientOutcomes #AgreementsLibrary
-
The insulin market in the U.S. is experiencing significant changes in pricing and reimbursement. Recent reductions in list prices by Novo Nordisk, Eli Lilly, and Sanofi, combined with increasing biosimilar competition and new legislative measures like the Inflation Reduction Act, are reshaping the landscape. Payers now face the challenge of implementing value-based coverage decisions to balance optimal health solutions and low out-of-pocket costs for patients. Read the full Lyfegen article to understand the latest developments: #InsulinPricing #Healthcare #PharmaNews #MarketAccess
Finding the right insulin products for payers to cover
Lyfegen auf LinkedIn
-
At Lyfegen, we extend our heartfelt congratulations to Josep Maria Guiu on being recently elected as the President of the Societat Catalana de Farmàcia Clínica. His dedication and leadership have played a key role in our recent partnership with the Consorci de Salut i Social de Catalunya. We are confident that his new role will bring significant advancements in the hospital pharmacy sector in Catalonia. Congratulations, Josep!
Dr. Josep Maria Guiu, Vice President for Europe of the FIP Hospital Pharmacy Section, has been recently elected as the President of the Catalan Society of Clinical Pharmacy (Societat Catalana de Farmàcia Clínica). The Catalan Society of Clinical Pharmacy is a scientific society within the framework of the Academy of Medical and Health Sciences of Catalonia and the Balearic Islands. It brings together health science professionals, primarily pharmacists from various sectors, including community pharmacy, primary care, hospital pharmacy, administration, and academia. Congratulations, Josep M. Guiu! We look forward to your leadership in advancing the practice and impact of clinical pharmacy. #ClinicalPharmacy #Healthcare #PharmacyLeadership #PharmaceuticalCare #PharmacyProfessionals Societat Catalana de Farmàcia Clínica FIP Hospital Pharmacy Section Sociedad Española de Farmacia Hospitalaria (SEFH) The European Association of Hospital Pharmacists (EAHP) Consejo General de Colegios Farmacéuticos Consorci de Salut i Social de Catalunya
-
-
We are excited to share that Lyfegen has been recognized in the F6S list of Top Healthcare Companies and Startups in Switzerland! F6S is a global online community connecting over 4 million founders and startups with resources such as funding, accelerators, grants, and networking opportunities. Being featured on this list is a tremendous honor for us. It is inspiring to see so many innovative and dedicated healthcare startups striving alongside us to make a difference in the industry. Are you curious to know more about our value-based solutions? Book a free demo with us today: lyfegen.com/demo #F6S #healthcareinnovation #Milestone #healthtechswitzerland
-